Sitryx Therapeutics Ltd. has disclosed nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators reported to be useful for the treatment of inflammatory disorders.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche, Inc. have described fluorescent probes acting as monoglyceride lipase (MGLL; MAGL) inhibitors reported to be useful for diagnostic imaging of MAGL.
University of Ottawa has synthesized ferroptosis inhibitors reported to be useful for the treatment of cancer, diabetes, myocardial infarction, amyotrophic lateral sclerosis, sepsis, shock, transplant rejection and Alzheimer’s dementia.
Ensem Therapeutics Inc. has disclosed quinazoline derivatives acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
The U.S. Patent and Trademark Office (USPTO) published new enablement guidelines Jan. 10 to provide more consistency across technologies to ensure patent applications truly enable the breadth of their claims in keeping with the Supreme Court’s unanimous decision last year in Amgen Inc. v. Sanofi SA.
In what represents the first patenting from Immersive Reality Group LLC, the company’s co-founders describe their Intellighealth system for detecting the early onset of respiratory diseases using artificial intelligence and wearable remote health monitoring technologies.
Acadia Pharmaceuticals Inc. has described G protein-coupled receptor GPR88 agonists reported to be useful for the treatment of attention deficit hyperactivity disorder (ADHD), substance abuse and dependence, schizophrenia, Tourette syndrome, bipolar disorder, Huntington's disease, Alzheimer's disease and Parkinson's disease.
Insilico Medicine IP Ltd. has divulged cyclin-dependent kinase 8 (CDK8) and/or CDK19 dual inhibitors reported to be useful for the treatment of autoimmune diseases and cancer.
RSS
